Author(s): Rehan Haider

Email(s): Email ID Not Available

DOI: 10.52711/2231-5713.2023.00013   

Address: Rehan Haider
Department of Pharmacy, University of Karachi, Riggs Pharmaceuticals Karachi - Pakistan.
*Corresponding Author

Published In:   Volume - 13,      Issue - 1,     Year - 2023


ABSTRACT:
Vaccine have a history that started late in the 18th century. From the late 19th century, Vaccine could be developed in the laboratory, However, In the 20th century it became possible to develop vaccine based on Immunologic makers In the 21st century molecular biology permits vaccine development that was not possible before. In the history of science is the impact of vaccines on human longevity and health over 300 years elapsed since the first vaccine was discovered. In short article it is not possible to do justice to a subject that encompases immunology, molecular biology, and public health, but several more extensive sources are available to the interested reader 1-5 rather than attempting a chronological narrative, In current articles that describe novel technologies, it is often said that they will enable " rational" development of vaccines. The opposite of rational is irrational, but presumably the writer mean to contrast rational with "empiric" However, in fact vaccine development has been based on rational choices ever since the mid 20th century, when the immunology advanced to the point of distinguishing protection mediated by antibody and that mediated by lymphocytes, and when passage in cell culture permitted the selection of attenuated mutants, After the point successful vaccine have been " rationally" developed by protection studies in animal, by inference from immune response shown to protect against repeated natural infection (the so called mechanistic correlates of protection) 6 and from the use of passive administration of antibodies against specific antigens to show that those antigens should be included in vaccines.


Cite this article:
Rehan Haider. Vaccine through Centuries. Major Cornerstone of Global Health. Asian Journal of Pharmacy and Technology. 2023; 13(1):65-9. doi: 10.52711/2231-5713.2023.00013

Cite(Electronic):
Rehan Haider. Vaccine through Centuries. Major Cornerstone of Global Health. Asian Journal of Pharmacy and Technology. 2023; 13(1):65-9. doi: 10.52711/2231-5713.2023.00013   Available on: https://ajptonline.com/AbstractView.aspx?PID=2023-13-1-13


REFERENCES:
1.    Plotkin SA (2011) History of vaccine Development (Springer, New York)
2.    Artenstein Aw, ed (2010) vaccines, a Biography (Springer New York)
3.    Plotkin SL, Plotkin SA(2013) A short history of vaccination.Vaccine eds Plotkin SA, Orenstein WA, offit PA (Elsevier- Saunders Philadelphia) 6th Ed pp 1 - 13
4.    Plotkin SA, Plotkin SL, (2011) The development of vaccines, how the past led to the future Nat Rev Microbiol 9(12) 889 - 893
5.    Baxin H (2011) vaccination. A History from Lady Montagn to Genetic Engineering (John Libbey Eurotext, Esher UK)
6.    Plotkin SA, Gilbert PB(2012) Nomenclature for immune Correlates of protection after vaccination.Clin infect Dis 54(11) 1615-1617
7.    Baby D (1999) Edward Jenner's inquiry after 200 years BMJ 318-7180- : 390
8.    Pasteur L (1880) De I' atténuation du Virus du cholera des Poules.CR Acad sci Paris 91: 673- 680
9.    Pasteur L (1885) Méthodes Pour Prévenir LA rage après morsure CR Acad sci Paris 101, 765-772
10.    Pasteur L .Chamberland CF, Roux E(1881) sur la vaccination charbonneuse CR Acad sci paris 92 1378- 1383
11.    Calmette A (1927) la vaccination de I' homme contre la Tuberculosis per ie " BCG" (Masson Paris)
12.    Sellards Aw, Laigret J (1932) vaccination de I ' homme Contreras la fievre Jaune.CR Acad Sci Paris 194 1609- 1611
13.    Teller M, Smith HH (1937) effect of prolonged cultivation in vitro upon pathogenicity of yellow fever J exp Med 65(6) 767- 786
14.    Koprowski H, Jervis GA, Norton TW(1952) immune responses in human volunteers upon oral administration of a rodent - adapted strain of poliomyelitis virus Am j Hyg 55(1) 108-124
15.    Fox JP, koprowski H, con well DP, Black J, Gelfand HM, (1957) study of anti rabies immunization of man: observation with HEP Flirt and other vaccines, with without hyper immune serum, in primary and recall immunization Bull world Health organization 17(6) 869- 904
16.    Enders JF, Weller TH, Robbins FC(1949) cultivation of the Lansing Strain of Poliomyelitis virus in Cultures of various human embryonic tissues, Science 109(2822)85-87
17.    Sabin AB, Hennessen WA, Winsser J (1954) studies on variants of Poliomyelitis virus, 1 experimental segregation and properties of a virulent of three immunologic type.J Exp Med 99(6) 551-576
18.    Katz SL et al (1960) studies on an attenuated measles virus vaccine Viii general summary and evaluation of the result of vaccination Am J Dis Child 100- 942- 946
19.    Hillerman MR, BuynaK EB, Weibel RE, Stokes J, Jr (1968) live, attenuated mumps- virus vaccine.N Engl J Med 278(5) 227-232
20.    Plotkin SA Farquhar JD, Katz M, Buser F (1969) attenuation of RA 27-3 Rubella virus in W1 -38 human diploid cells Am J Dis child 118(2)178- 185
21.    Takahashi M, Okuno Y, Otsuka T, Osama J, Takamizawa A (1975) Development of a live attenuated varicella vaccine, Biken J 18(1) 25- 33
22.    Pliaka V, Kyriako poulovZ, MerkouLatos P (2012) Risk associated with the use of live attenuated vaccine polio virus strain and the strategies for control and eradication of paralytic poliomyelitis, Expert Rev vaccine 11(5) 609- 628
23.    Top FH, Jr Buesher EL, Bancroft WH, Russell PK(1971) immunization with live types 7 and 4 adenovirus vaccines.
24.    Bernstein DL, et.al (1998) safety and immunogenicity of live attenuated human rotavirus vaccine 89-12 vaccine 16(4) 381-387
25.    Trent DW, MinorP, jiva Paisarnpong T, ShinJ, WHO working Group on the Quality safety and efficacy of Japanese Encephalitis vaccine live attenuated for human use Bangkok, Thailand 21-23Feb 2012 Biological 41(6) 450- 457
26.    Massab HF, De Borde DC (1985) development and characterization of cold adapted viruses for use as live virus, vaccine -3 (5) 355- 369
27.    Francis T, jr, Salk JE, Brace WM, (1946) The protective effect of vaccination against epidemic influenza B J Am Med Assoc 131-275- 278
28.    Clork HF, Offit PA, Plotkin SA, Heaton PM(2006) The new pentavalent Rotavirus vaccine composed of bovine (strain w c 3) human Rotavirus reassortants, Pediatr infect Dis J 25 (7) 577-583
29.    Hoffmann E, Neumann, Kawaoka Y, HobomG, Webster RG(2000) A DNA transfection system for generation of influenza A virus from eight plasmid proc Natl Acad from eight 97(11) 6108- 6113
30.    Kapikian Az, et.al (1989) strategies for the development of rota vaccine against infantile diarrhea with update on clinical trials of Rotavirus vaccine, Adv Exp Med Biol 257- 67- 89
31.    Clerk HF, Borian FF, Plotkin.SA 161(6) 1099- 1104
32.    Salmon De, Smith T (1886) on a new method of producing immunity from contagious disease Am vet Rev 10.63.69
33.    Roux.ET, chamberland CE (1887) immunité contre la septicémie conférence par des substance soluble Am inst Pasteur (Paris) 1: 561- 572
34.    Wright AE, Semple D (1897) Remarks on vaccination against typhoid fever BMJ (1883) 256-259
35.    Pfeiffer R, Kolle W, (1896) experimentelle untersuchungen zur frage der, schutzimpfung des Menschen Gegen typhus abdominalis DTSCH Med Wochenschr 22.735- 737
36.    Haffkine WM (1899) protective inoculation against plaque and cholera BMJ 1: 35-36
37.    Perish HJ (1965) A history of immunization E and s livingstone Edinburgh
38.    Pfeffer R, Kolle W, (1896) experimentelle untersuchungen zur frage des schutzimp tung des Menschen gegen typhus abdominalis Dtsch Med wochenschr 22 735- 737 German
39.    Holmgren J et al (1987) An oral B submit whole cell vaccine against cholera from concept to successful field trial Adv exp Med biol 2168- 1649- 1660
40.    Medsen C (1933) vaccination against whooping cough. JAMA 101 187 188
41.    Sauer LW (1946) whooping cough prevention and treatment Med clin. North Am 30 45 59
42.    Shapiro shapin CG (2010) pearl Kendrick, Grace Eldering and the pertussis vaccine Emerg infect Dis 16(8) 1273- 1278
43.    Glenny AT, Hopkins BE, (1923) diphtheria toxoid as an immunisqutes agent Br J Exp part 4 283- 288
44.    Ramon C (1923) sur..le pouvoir floculant et al sar les propriétés immunisantes d une toxin diphtérique re din anatoxique CR Acad sci Paris 177 1338 1340
45.    Francis T, jr magil TP(1936) vaccination of human subject with virus of human influenza prov soc exp Biol med 33 604 606
46.    Salk JE et al (1954) formaldehyde treatment and safety testing of experimental poliomyelitis vaccine Am J public health nations health 44(5) 563- 570
47.    Provost PJ et al (1986) An inactivated hepatitis A viral vaccine of cell culture origin J Med viral 19 (1) 23- 31
48.    Yamashita T, Ishikama, N, Hojo F, shi mad a F OnOK (1970) Japanese encephalitis purified vaccine II purity of the mouse brain vaccine purified By ultracentrifugation Biken J 13(1) 25- 38
49.    Fischer M, lindsey N, staples JE, Hills S, centre for disease control and prevention (CDC) (2010) japanese encephalitis vaccine Recommendations of the Advisory committee on immunization practices (ACIP) MMWR Recomm PCP 59(PR)(1)- 1- 27
50.    Kuinz C (1962) Aktiv und passive immunoprophylaxw der Frühsommer     Meningoenzephalitis(FSME) Ar2neimitelforschurg 28 - 1806
51.    Gotschlich Ec, liv Ty, Artenstein MS(1969) Human immunity to the meningococcus 3 Preparation and immunochemical properties of the group A, group B, and Group C meningococcal polysaccharides J Exp Med 129 (6) 1349- 1365
52.    Heidelberger M Macleod CM, Di Lapi MM (1948) the human antibody response to simultaneous injection of six specific polysaccharide of pneumococcus / Exp Med 88 (3) 369- 372
53.    Austrian R, (1989) pneumococcal polysaccharides vaccine, Rev infect Dis 11 (supply3) 5598- 5602
54.    Anderson P, Peter G, Johnston RB, jr Wettlerlow LH, Smith DH(1972) immunization of human with polybo phosphate, the capsular antigen of Haemophilus influenzae, type b J chin invest 51(1) 39-44
55.    Schneerson R, Barrera O, Sulton A, Robbins JB, immunogenicity of Haemophilus influenzae type b polysaccharides protein conjugate J Exp Med 157(2) 361- 376
56.    Landy M, Gaines S, Seal JR, Whiteside JR, (1954) Antibody response of man to three types of Anti typhoid immunizing agent heat - phenol fluid vaccine acetone - dehydrated vaccine, and isolated V1 and O antigens Am J public Health Nations Health 44 (12) 1572- 1579
57.    Avery OT, Goebel WF (1929) chemo immunological specificity of synthetic sugar - protein antigen, J EXP Med 50(4) 533- 550
58.    Cate TR, couch R, Kasel JA, Six HR(1977) clinical trials of monovalent influenza A/ new jersey /76 virus vaccine in.adults Reactogenicity, antibody response, and antibody persistence J infect Dis 13 (suppl) 5450- 5455
59.    Sato Y, Sato H, (1999) development of acellular pertussis vaccines, Biologicals 27(2) 61-69
60.    Edward KM, Decker MD(2013) pertussis vaccine, vaccines eds plotkin SA, orenstein WA, offit PA(Elsevier, Philadelphia) 6th Ed pp.427- 482
61.    Ivind BE, Weikos, SL (1988) Recent advances in the development of an improved, human anthrax vaccine, Eur J Epidemiol 4 (1) 12-19
62.    Wikbr TJ, Plotkin SA, Grella DW (1973) Human cell culture Rabies vaccine, Antibody response in man, JAMA 224(8(1170- 1171
63.    Hilleman MR, McAlear WJ, Buyna K, EB, Mclean AA ((1983) The preparation and safety of hepatitis B vaccine J infect 7 (suppl) 1-3- 8
64.    Valenzuela P, Mcdina A, Rutter WJ, Ammerer G, Hail BD(1982) synthesis and assembly of hepatitis B virus Surface antigen particles in Yeast Nature 298(5872) 347- 350.
65.    Germanier R, Fuer E (1975) isolation n and characterization Gal E mutant ty 21x salmonella typhi A candidate strain for a live, oral typhoid vaccine J infect Dis 131(5) 553- 558
66.    Levine MM, et al (1988) safety, immunogenicity and efficacy of recombinant live oral cholera vaccine, CVD 103 and CVD 103 - HgR lancet 2 (8609).467- 470
67.    Guy B et.al (2010) preclinical development of YFV 17D - based chimeric vaccine against dengue, west Nile and Japanese encephalitis viruses, vaccine 28 (3) 632- 649
68.    Kim baver R, Booy F, cheng N, lowy DR, Schiller JT (1992) papiloma virus Li major capsid protein self assembles into virus like particles that are highly immunogenic .procNatl Acad sci USA 84(24) 12180- 12184
69.    McNeil(2006) who invented The VLP cervical cancer vaccine J Natl cancer inst 98(7) 433
70.    Huber VC (2014) influenza vaccine, From whole virus preparation to recombinant proteins Technology, Expert Rev  vaccine 13 (1) 31-42
71.    Johansson BE, Bucher DJ, Kilbourne ED (1989) purified influenza virus hemagglutinin and neuraminidase are equivalent in stimulation of antibody response but induce contrasting type of immunity to infection J Virol 63(3) 1239- 1246
72.    FikrigE, Bart hold SW, kantor FS, Flaveu RA (1990) protection of mice against the Lyme disease agent by immunizing with recombinant OSPA science 250(4980) 553- 556
73.    Steere AC, et al Lyme disease vaccine study Group (1998) vaccination against lyme disease with recombinant Borrelia burgdorferi outer - surface lipoprotein A with adjuvant N Engl J Med 339(4) 209- 215
74.    Giuliani MM, et.al (2006) A universal vaccine for serogroup B meningococcus, Proc Natl Acad sci USA 103(29) 10834- 10839
75.    Rappuoli R(2000) Reverse vaccinology curr opin Microbiol 3(5)445- 450
76.    Liang ZL, et al (2013) progress on the research and development of inactivated Ev 71 whole - virus vaccine Hvm vaccine immunother 9 (8) 1701- 1705
77.    Flingai S, et.al.(2013) synthetic DNA vaccine, improved vaccine potency electroporation and co delivered genetic adjuvants.Front immunol 4: 354
78.    Kallen KJ, et al (2013) A novel, disruptive vaccination technology, self vaccine immunother 9(10) 2263- 2276
79.    Rerks- Ngarm S, et al: MOPH TAVEG investigators (2009) vaccination with ALVAC and AIDSVAX to prevent HIV -1 infection in Thailand N Engl J Med 361(23) 2209- 2220
80.    Monath TP, et al.(2002) clinical proof of principle for chimer vax Recombinant live attenuated 20(7-8) 1004- 1018
81.    Dudek T, Knipe DM(2006) Replication Defective viruses as vaccine vector virology 344(1) 230- 239
82.    Mastelic B, et al (2010) mode of action of adjuvants.Implications for vaccine safety and design Biologicals 38(5) 594- 601
83.    Julian JP, et al (2013) crystal structure of a soluble cleaved HIV- 1 envelope trimer science 342(6165) 1477- 1483
84.    Lis, Nekaya HI, Kazmin DA, OhJ2 pulendran B (2013) systems biological approaches to measures and understand vaccine immunity in humans, semin immunol 25(3) 209- 218

Recomonded Articles:

Author(s): Phatak Atul A., Chaudhari Praveen D.

DOI:         Access: Open Access Read More

Author(s): Dhadde Gurunath S., Mali Hanmant S., Raut Indrayani D., Nitalikar Manoj M., Bhutkar Mangesh A.

DOI: 10.52711/2231-5713.2021.00025         Access: Open Access Read More

Author(s): Sunil Kumar, Anil Kumar, Vaibhav Gupta, Kuldeep Malodia, Pankaj Rakha

DOI:         Access: Open Access Read More

Author(s): Girishchandra R., Mandake, Shital S. Shinde, Vishal Y. Belaskar, Asha M. Jagtap, Ganesh B. Vambhurkar, Manoj M. Nitalikar

DOI: 10.5958/2231-5713.2018.00033.8         Access: Open Access Read More

Author(s): Poonam R. Songire, Smita S. Aher, R. B. Saudagar

DOI: 10.5958/2231-5713.2015.00031.8         Access: Open Access Read More

Author(s): Godbole Ajeet Madhukar, Patel Bhautik V, Somnache Sandesh Narayan, Prajapati Ashish R, Yadav Pradeep

DOI: 10.5958/2231-5713.2017.00004.6         Access: Open Access Read More

Author(s): S. Kumara Swamy, G. Arun, Bethi Srinivas, Agaiah Goud B

DOI: 10.5958/2231-5713.2016.00014.3         Access: Open Access Read More

Author(s): M. Karthika, K. Pramod, K.C. Ajithkumar, U. S. Jijith

DOI: 10.5958/2231-5713.2016.00025.8         Access: Open Access Read More

Author(s): Subhashis Debnath, Gampa Vijay Kumar, S.V. Satyanarayana

DOI:         Access: Open Access Read More

Author(s): B. Ranga Nayakulu, Nakka Ravi Kumar, Ch. Kiran Kumar, P. Raja Abhilash

DOI: 10.5958/2231-5713.2016.00012.X         Access: Open Access Read More

Author(s): Paun J.S., Tank H.M.

DOI:         Access: Open Access Read More

Author(s): Priyanka V Dhalkar, Shivani S Jagtap, Suraj T Jadhav, Myuresh R. Redkar., Biradev S Karande

DOI: 10.5958/2231-5713.2019.00034.5         Access: Open Access Read More

Author(s): Indu Rathore

DOI: 10.5958/2231-5713.2017.00014.9         Access: Open Access Read More

Author(s): Swati Paul, Dibyajyoti Saha, Srikanta Chowdhury

DOI:         Access: Open Access Read More

Asian Journal of Pharmacy and Technology (AJPTech.) is an international, peer-reviewed journal, devoted to pharmaceutical sciences...... Read more >>>

RNI: Not Available                     
DOI: 10.5958/2231–5713 


Recent Articles




Tags